AssetMark’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TGTX
AssetMark's TGTX Position: Q3 2026 in Review
AssetMark reduced its TG Therapeutics (TGTX) stake by 5.6% in Q3 2026, selling an estimated $541 and leaving 170 shares worth $9.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.
AssetMark first reported a position in TGTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $9.9K in Q2 2026. 369 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.
- AssetMark held 170 shares of TG Therapeutics worth $9.48K as of Q3 2026.
- AssetMark sold 10 TG Therapeutics shares in Q3 2026, an estimated $541.
- TG Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2526 holding.
- AssetMark first reported a position in TG Therapeutics in Q3 2024 and has held it in 9 quarters since.
- AssetMark's TG Therapeutics position peaked at $9.9K in Q2 2026.
- 369 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.